JP2005503383A5 - - Google Patents

Download PDF

Info

Publication number
JP2005503383A5
JP2005503383A5 JP2003520752A JP2003520752A JP2005503383A5 JP 2005503383 A5 JP2005503383 A5 JP 2005503383A5 JP 2003520752 A JP2003520752 A JP 2003520752A JP 2003520752 A JP2003520752 A JP 2003520752A JP 2005503383 A5 JP2005503383 A5 JP 2005503383A5
Authority
JP
Japan
Prior art keywords
adrenal
pharmaceutical composition
hydrocortisone
disease
caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003520752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005503383A (ja
Filing date
Publication date
Priority claimed from GBGB0119848.0A external-priority patent/GB0119848D0/en
Application filed filed Critical
Publication of JP2005503383A publication Critical patent/JP2005503383A/ja
Publication of JP2005503383A5 publication Critical patent/JP2005503383A5/ja
Pending legal-status Critical Current

Links

JP2003520752A 2001-08-15 2002-08-08 遅らせかつ持続された薬剤放出 Pending JP2005503383A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119848.0A GB0119848D0 (en) 2001-08-15 2001-08-15 Delayed and sustained drug release
PCT/GB2002/003631 WO2003015793A1 (en) 2001-08-15 2002-08-08 Delayed and sustained drug release

Publications (2)

Publication Number Publication Date
JP2005503383A JP2005503383A (ja) 2005-02-03
JP2005503383A5 true JP2005503383A5 (enExample) 2006-01-05

Family

ID=9920405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003520752A Pending JP2005503383A (ja) 2001-08-15 2002-08-08 遅らせかつ持続された薬剤放出

Country Status (6)

Country Link
US (1) US20050037074A1 (enExample)
EP (1) EP1416938A1 (enExample)
JP (1) JP2005503383A (enExample)
CA (1) CA2493349A1 (enExample)
GB (1) GB0119848D0 (enExample)
WO (1) WO2003015793A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100824491B1 (ko) * 2001-10-05 2008-04-22 콤비네이토릭스, 인코포레이티드 면역염증 질환의 치료를 위한 조합
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20080003213A1 (en) * 2006-05-22 2008-01-03 Jan Lessem Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels
GB0623740D0 (en) * 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
WO2009038708A1 (en) * 2007-09-19 2009-03-26 Combinatorx, Incorporated Therapeutic regimens for the treatment of immunoinflammatory disorders
EP2231129A4 (en) * 2007-12-17 2013-01-30 Zalicus Inc THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
GB0817120D0 (en) * 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
US20120183610A1 (en) * 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
MX337429B (es) * 2010-05-20 2016-03-04 Duocort Pharma Ab Posologia y administracion de composiciones basadas en glucocortticoides.
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
ES2906778T3 (es) 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
DE10012555A1 (de) * 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung

Similar Documents

Publication Publication Date Title
JP2005503383A5 (enExample)
JP2007502287A5 (enExample)
JP2004210798A5 (enExample)
HRP20120264T1 (hr) Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe
JP2006520797A5 (enExample)
JP2007514005A5 (enExample)
JP2004518656A5 (enExample)
JP2005533005A5 (enExample)
ATE493132T1 (de) Arzneimittel umfassend wenigstens ein gestagen
JP2011506412A5 (enExample)
TW200635617A (en) Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form
WO2008062446A3 (en) An extended release composition of levetiracetam, which exhibits no adverse food effect
DE602005024470D1 (de) Verfahren zur Herstellung von Drospirenon
JP2010539153A5 (enExample)
WO2005011614A8 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
JP2008534533A5 (enExample)
US11266646B2 (en) Use of chymase inhibitors for the treatment of endometriosis, post operative fibrosis and diseases which are characterized by fibrosis formation
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
Hooiveld et al. Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
WO2005011616A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
JP2007517913A5 (enExample)
JP2008521783A5 (enExample)
JP2004531567A5 (enExample)